Traders should monitor upcoming clinical milestones, especially SAFEGUARD trial enrollment progress and biomarker/data readouts. Positive Phase 2b results could significantly re-rate the stock given the lack of disease-modifying therapies in T1D and SAB-142’s potential best-in-class profile.
Price Chart
Executive Summary
SAB Biotherapeutics released Phase 1 data for its investigational therapy SAB-142 in established type 1 diabetes (T1D), showing early signals of C-peptide preservation — a marker of endogenous insulin production — in treated patients compared to placebo. While the cohort was small (n=6) and results are exploratory, the data support the drug's biological mechanism and provide momentum ahead of the ongoing Phase 2b SAFEGUARD trial in new-onset T1D, with topline results expected in 2H 2027.
Key Facts
- Phase 1 T1D cohort included 6 adult patients: 4 received SAB-142 (2.5 mg/kg), 2 received placebo.
- SAB-142-treated patients (n=4) showed no decrease in C-peptide at Day 120 vs. baseline; mean levels were preserved or increased.
- One placebo patient showed a decline in C-peptide consistent with expected disease progression; the second placebo patient discontinued early.
- Data align with SAB-142’s mechanism of action and prior biomarker evidence of T-cell modulation.
- SAFEGUARD Phase 2b registrational trial in new-onset T1D is ongoing, with global enrollment and topline data expected in 2H 2027.
Financial Impact
No direct financial impact from this release; potential long-term value hinges on Phase 2b success in a high-unmet-need indication.
Risk Factors
- Small sample size (n=4 active, n=1 placebo) limits statistical power and generalizability.
- Phase 1 data are exploratory and from established T1D patients, while the registrational trial is in new-onset T1D — a different population.
- Forward-looking statements carry high uncertainty; clinical failure risk remains significant.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3252675 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 7, 2026 12w ago | 8-K | $3.90 $3.17 | ▼ −18.72% | ▼ −20.71% | $2.98 (−23.59%) |
May 29, 2026 18w ago | Press Release | $3.60 $3.62 | ▲ +0.56% | ▼ −0.63% | $2.98 (−17.22%) |
May 12, 2026 20w ago | Press Release | $3.62 $3.85 | ▼ −6.35% | ▼ −1.97% | $2.98 (+17.68%) |
Mar 19, 2026 28w ago | Press Release | $3.75 $3.90 | ▲ +4.00% | ▼ −10.42% | $2.98 (−20.53%) |
Mar 19, 2026 28w ago | 8-K | $3.78 $3.90 | ▼ −3.17% | ▲ +11.17% | $2.98 (+21.16%) |
Mar 18, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 17, 2026 28w ago | Press Release | $3.70 $3.38 | ▲ +8.65% | ▲ +20.17% | $2.98 (+19.46%) |
Mar 10, 2026 29w ago | Press Release | $4.10 $3.36 | ▼ −18.05% | ▼ −29.73% | $2.98 (−27.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access